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ABSTRACT
Introduction: Peptide receptor radionuclide therapy (PRRT) of patients with 
somatostatin receptor expressing neuroendocrine neoplasms has shown promising 
results in clinical trials and a recently published phase III study.
Methods: In our center, 2294 patients were screened between 2004 and 2014 
by 68Ga somatostatin receptor (SSTR) PET/CT. Intention to treat analysis included 
1048 patients, who received at least one cycle of 90Yttrium or 177Lutetium-based PRRT. 
Progression free survival was determined by 68Ga SSTR-PET/CT and EORTC response 
criteria. Adverse events were determined by CTCAE criteria.
Results: Overall survival (95% confidence interval) of all patients was 51 months 
(47.0-54.9) and differed significantly according to radionuclide, grading, previous 
therapies, primary site and functionality. Progression free survival (based on PET/
CT) of all patients was 19 months (16.9-21), which was significantly influenced by 
radionuclide, grading, and origin of neuroendocrine neoplasm. Progression free survival 
after initial progression and first and second resumption of PRRT after therapy-free 
intervals of more than 6 months were 11 months (9.4-12.5) and 8 months (6.4-9.5), 
respectively. Myelodysplastic syndrome or leukemia developed in 22 patients (2.1%) 
and 5 patients required hemodialysis after treatment, other adverse events were rare.
Conclusion: PRRT is effective and overall survival is favorable in patients 
with neuroendocrine neoplasms depending on the radionuclide used for therapy, 
grading and origin of the neuroendocrine neoplasm which is not exactly mirrored in 
progression free survival as determined by highly sensitive 68Ga somatostatin receptor 
PET/CT using EORTC criteria for determining response to therapy.
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INTRODUCTION
Neuroendocrine neoplasms (NENs) arise most 
frequently in the gastroentero-pancreatic system and lungs. 
These neoplasms originate in scattered endocrine cells of 
the diffuse neuroendocrine system and are biologically 
very heterogeneous [1]. Two groups of NEN behave 
biologically and clinically distinctively different; the well 
differentiated slowly growing neuroendocrine tumors with 
an excellent to good prognosis and poorly differentiated 
fast growing neuroendocrine carcinomas with a poor 
prognosis. Grading of NENs is performed by Ki67 index. 
G1 and G2 neuroendocrine tumors have a Ki67 index 
of 20% or below whereas neuroendocrine carcinomas 
have a Ki 67 index of more than 20%. Neuroendocrine 
carcinomas are defined by small or large cell morphology. 
In addition, the new WHO classification of pancreatic 
NENs includes the newly created well differentiated 
neuroendocrine tumors with a proliferation of up to 
50% as neuroendocrine tumor G3 [2, 3]. NENs may be 
functionally active due to the autonomous secretion of 
biogenic amines or peptide hormones such as serotonin, 
gastrin or insulin causing characteristic functional 
syndromes [4].
The majority of well-differentiated NENs 
overexpress receptors of the 5 subclasses of somatostatin 
receptors (SSTRs), most frequently receptors 2 and 5. 
Activated SSTRs have anti-secretory and anti-proliferative 
activity, and are targeted by stable somatostatin analogues 
for treatment of functional syndromes and to reduce tumor 
growth of NENs [5–7]. In addition, SSTR are utilized to 
visualize NENs by molecular imaging. SSTR scintigraphy 
uses stable somatostatin analogues coupled to short-
lived radionuclides such as 111Indium or 99mTechnetium. 
The more recently developed SSTR PET/CT involves 
68Gallium (68Ga) as a positron emitter, coupled to stable 
somatostatin analogues. This technique is more sensitive, 
faster with much lesser radiation exposure, compared to 
the standard SSTR scintigraphy [8]. Netspot, the first 
kit for the preparation of 68Ga-DOTATATE for PET/
CT imaging of NENs was recently approved by the US 
FDA (http://www.fda.gov/Drugs/InformationOnDrugs/
ucm508921.htm).
Coupling beta- and/or gamma-emitting 
radionuclides to stable somatostatin analogues permits 
internal radiation of SSTR-expressing NENs by peptide 
receptor radionuclide therapy (PRRT). 90Yttrium (90Y) and 
177Lutetium (177Lu) are used as radionuclides and chelated 
to stable somatostatin analogues such as DOTATATE 
and DOTATOC [9, 10]. Numerous phase I and phase II 
studies have shown favorable progression-free survival 
(PFS) and overall survival (OS) in NEN patients compared 
to historical controls [9–11]. Recently, a phase III study 
(NETTER-1 trial) has compared 4 cycles of PRRT, each 
using 7.4 GBq of 177Lu-DOTATATE (Lutathera®) together 
with 30 mg Octreotide-LAR every 4 weeks, to high dose 
somatostatin analogue therapy with 2 x 30 mg Octreotide-
LAR every 4 weeks. Patients with progressive NENs of 
small bowel under treatment with somatostatin analogues 
and with SSTR expression were included, and 230 were 
randomized in a 1:1 ratio. In the control group, median 
PFS was 8.4 months, whereas it was not reached yet in the 
Lutathera® group (estimation 40 months). The hazard ratio 
was 0.209 (95% CI, 0.129-0.33) in favor of Lutathera®. 
Adverse events were rare and the treatment was well 
tolerated [12].
Standardized uptake values (SUVs) of SSTR PET/
CT predict absorbed dose and response to PRRT [13–16]. 
Here, we present OS and PFS in 1048 patients treated 
with at least one cycle of PRRT using 90Y or 177Lu, which 
were selected and re-staged by 68Ga-SSTR PET/CT 
(Figure 1). Response to PRRT evaluated by radiological 
criteria (RECIST 1.1) has been reported previously in two 
subgroups of 56 and 200 patients, respectively [11, 17].
RESULTS
Patient characteristics
The majority of patients (593/1048) were males 
(56.6%) and 455 (43.4%) were females. Most patients 
(559/1048) were between 41 and 60 years at diagnosis 
(53.3%) whereas 393 (37.5%) were older than 60 
years. At diagnosis, 96 patients (9.2%) were 40 years 
or younger. This group included 1 patient less than 10 
years of age, 5 patients between 11 and 20 years, 24 
patients between 21 and 30 and 76 patients aged between 
31 and 40 years. Most patients received PRRT with 
177Lu; 378 as monotherapy (36.1%) and 513 (48.9%) in 
combination with 90Yttrium either as a combination of 
both radionuclides in one cycle (TANDEM) or sequential 
(DUO). Only 157 patients (15%) received 90Y-DOTATATE 
or -DOTATOC as monotherapy. Mean administered 
radioactivity was 18.84 GBq with a minimum of 1.4 GBq 
and a maximum of 63.9 GBq. Most patients (247 and 
399, respectively) had well differentiated NENs of grade 
1 (23.6%) or grade 2 (38.1%). A minority of 67 patients 
(6.4%) had well differentiated NENs grade 3. Grading 
was not available in 335 patients (31.9%), which were 
diagnosed before WHO criteria were published and no 
tissue was available anymore for analysis. These patients 
were included as a separate group. The majority of patients 
had been pretreated by one or more other therapies 
(surgery, somatostatin analogs, chemotherapy, molecular 
therapy). PRRT was performed as first-line treatment 
in 119 patients (11.4%) with mostly ileum NENs. More 
than 3 other therapies before PRRT had been performed 
in 209 patients (19.9%), whereas 417 patients (39.8%) 
had received 2-3 therapies and 303 (28.9%) had had one 
therapy. Primary tumors were localized in pancreas (384 
or 36.6%), small intestine (315 or 30.1%), lung (75 or 
7.2%), colon and rectum (52 or 5.0%), duodenum (22 or 
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2.1%), thymus and mediastinum (16 or 1.5%) stomach 
(15 or 1.4%), caecum and appendix (5 or 0.5%), others 
(13 or 1.2%) and 151 patients (14.4%) had tumors with 
unknown primary site. Other primary tumors included 
paragangliomas/pheochromocytomas (15 patients) and 
25 patients with medullary thyroid cancer. For statistical 
analysis, the group of others included other primary tumor 
as described above and primaries of duodenum, stomach, 
thymus, mediastinum, stomach, caecum and appendix.
Functional syndromes were present in 244 patients 
(23.3%), whereas 804 (76.7%) had no symptoms of 
hormone overproduction. Carcinoid syndrome was 
predominant (158 or 15.0%), followed by Zollinger-
Ellison syndrome/gastrinoma (46 or 4.4%), the syndromes 
caused by glucagonoma (16 or 1.5%), insulinoma (15 or 
1.4%) and the Werner-Morrison syndrome caused by 
VIPoma (8 or 0.7%).
Overall survival
Data and statistical analysis on overall survival (OS) 
is presented in Table 1. Of 1048 patients, 573 (54.7%) 
were alive with a median OS of 51 months (Figure 2A). 
Univariate analysis suggested a significant difference in 
OS for female gender, which was not corroborated by 
multivariate analysis (Table 1, Supplementary Figure 1A). 
Compared to the main age group at diagnosis between 40 
and 60 years, patients older than 60 years at diagnosis 
had a significantly shorter survival. Longer survival 
of patients younger than 40 years at diagnosis was not 
statistically significant in multivariate analysis (Table 
1, Supplementary Figure 1B). Best OS was achieved 
by a combination of 90Y- and 177Lu- for PRRT. Shortest 
survival was observed in patients treated exclusively 
with 90Y, while treatment with solely 177Lu resulted in an 
intermediate survival between the two extreme curves. 
These differences were highly statistically significant 
in univariate and multivariate analysis (Table 1, Figure 
3A). Grading of NENs was a strong predictor of overall 
survival. Best overall survival was achieved in the G1 
group, followed by G2. G3 NENs had the shortest overall 
survival with 23 months compared to 88 months in the G1 
group. Compared to G2, overall survival of G1 patients 
was significantly longer and significantly shorter in the G3 
group. The group of patients with G3 NENs included 18 
patients with a proliferation rate of more than 50%. These 
patients had a median overall survival of 8.7 months (95% 
confidence interval 0-21.1).
Patients with unknown grading had similar overall 
survival as G2 patients (Table 1, Figure 3B). Patients 
with more than 3 prior therapies had significantly lower 
survival whereas patients with only one previous therapy 
had a significantly longer survival (Table 1, Figure 4A). 
Site of origin of NENs was a predictor of median overall 
survival in one group only. Best survival was observed in 
patients with NENs of small bowel (69 months), which 
was statistically significant followed by CUP, others, 
pancreas and lung. In between the later groups, differences 
did not achieve statistical significance except for the 
heterogeneous group of other neuroendocrine neoplasias 
(Table 1, Figure 4B). This group included 25 patients with 
medullary thyroid cancer. These patients had a median 
overall survival of 32 months (23.8-43.5).
The majority of patients had no functional syndrome 
and a median overall survival of 51 months. Patients with 
carcinoid syndrome had a slightly lower median overall 
Figure 1: Flow chart of trial characteristics.
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Table 1: Patient characteristics and results of overall survival after start of PRRT
Analysis Number % Death patients Median 95% CI
Univariate analysis Multivariate analysis
p HR 95% CI p
All Patients 1048 100 475 51 47.0-54.9
Gender
Male 593 56.6 276 50 45.4-54.5 0.029 1
Female 455 43.4 199 53 47.3-58.6 0.84 0.7-1.02 0.07
Age
≤40 years 96 9.1 40 70 33.3-106.6 0.018 0.91 0.65-1.28 0.6
>40 and ≤60 years 559 53.4 248 54 46.6-61.3 1
>60 years 393 37.5 187 46 41.8-50.2 1.32 1.08-1.61 0.01
Radionuclide
Lutetium-177 378 36 143 44 36-1-52 <0.001 1.67 1.33-2.08 <0.001
Yttrium-90 157 15 100 24 17.4-30.6 2.89 2.27-3.69 <0.001
combined 513 49 232 64 51.7-64.3 1
Grading
G1 (Ki67<2%) 247 23.5 76 88 69.3-106.6 <0.001 0.65 0.49-0.86 0.0025
G2 (Ki67 3-20%) 399 38.1 162 51 44-57.9 1
G3 (Ki67>20%) 67 6.4 22 23 10.8-35.2 1.71 1.21-2.4 0.0023
unknown 335 32 143 46 41.5-50.4 1.04 0.84-1.29 0.74
Previous therapies
0 119 11.4 23 55 37.4-72.5 <0.001 0.72 0.46-1.12 0.15
1 303 29 119 62 52.1-71.8 0.7 0.55-0.88 0.0028
2-3 417 39.7 218 51 45-56.9 1
>3 209 19.9 115 41 35.3-46.6 1.39 1.1-1.76 0.01
Primary tumor
Bronchial 75 7.2 41 40 30.5-49.4 0.01 1.08 0.76-1.54 0.67
Pancreas 384 36.7 200 44 37.7-50.2 1
Small Intestine 315 30 120 69 53.7-84.2 0.57 0.44-0.75 <0.001
CUP 151 14.4 60 53 37.5-68.4 0.78 0.58-1.06 0.11
Other 123 11.7 54 47 38.8-55.1 0.7 0.51-0.95 0.02
Functional syndromes
Carcinoid 
syndrome 158 15 82 49 38.7-59.2 0.012 1.17 0.89-1.52 0.26
Gastrinoma 46 4.3 21 66 48.9-83 0.8 0.51-1.26 0.34
Insulinoma 15 1.4 10 32 9.7-54.2 1.06 0.56-2.03 0.86
Glucagonoma 16 1.5 7 127 nr 0.65 0.3-1.4 0.27
VIPoma 8 0.7 3 46 14.6-77.3 0.78 0.25-2.46 0.68
Other 1 0.1 1 52 nr 5.64 0.87-36.6 0.07
None 804 76.7 351 51 47-54.9 1
Abbreviations: nr: not reached; 95 CI: 95% confidence interval bold figures indicate significant results.
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survival of 49 months whereas patients with gastrinomas 
and glucagonomas had longer median overall survival 
of 66 and 127 months, respectively. Patients with 
insulinomas had a shorter median overall survival of 
32 months whereas patients with VIPomas were similar 
to non-functional patients or patients with carcinoid 
syndrome with a median overall survival of 46 months 
(Table 1, Supplementary Figure 3A).
Progression-free survival
Patients were restaged by 68Ga-SSTR PET/CT and 
tumor status was determined by RECIST and EORTC 
criteria. In addition, progression was defined as resumption 
of PRRT after an interval of more than 6 months or of 
any other therapy such as surgery, chemotherapy, local 
ablative therapies or molecular therapies according to 
Figure 2: Kaplan-Meier plots of overall survival (A) and progression-free survival 1 (B) after start of PRRT.
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the decision of the tumor board. As such, we determined 
progression-free survival after at least one cycle of PRRT 
(PFS1) including all 1048 patients (Table 2). Resumption 
of PRRT (2nd phase) was performed in 470 patients 
(PFS2; Supplementary Table 1) and again (3rd phase) in 
184 patients (PFS3; Supplementary Table 2).
Median PFS1 based on the EORTC PET criteria was 
19 months (Figure 2B). Detailed subgroup and statistical 
analysis of PFS1 is depicted in Table 2. Uni-variate 
analysis depicted statistically significant differences 
according to radionuclides (Figure 5A), grading (Figure 
5B), number of previous therapies (Figure 6B) and 
Figure 3: Kaplan-Meier plots of overall survival according to radioisotope (A) and grading (B).
Oncotarget16938www.oncotarget.com
origin of primary tumors (Figure 6A) but not gender 
(Supplementary Figure 2A), age (Supplementary Figure 
2B) and functionality (Supplementary Figure 3B) (Table 
2). Multi-variate analysis revealed that patients treated 
with 90Y exclusively had a significantly shorter PFS 
than patients treated with 177Lu or a combination of both 
radionuclides (Table 2, Figure 5A). Grading determined a 
significantly lower PFS only in patients with G3 tumors, 
but there was no significant difference in PFS between G1 
and G2 tumors, or between G2 tumors and tumors with 
unknown proliferation rate (Figure 5B, Table 2). Patients 
with G3 NENs with more than 50% proliferation rate had 
a median PFS1 of 5.7 months (nr-12.1) compared to all G3 
patients with a median PFS1 of 7 months (Table 2).
Figure 4: Kaplan-Meier plots of overall survival according to number of previous therapies (A) and primary tumors (B).
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Table 2: Patient characteristics and results of progression-free survival after start of PRRT
Number % Progressive patients Median 95% CI
Univariate analysis Multivariate analysis
p HR 95% CI p
All Patients 1048 100 774 19 16.9-21
Gender
Male 593 56.6 447 18 15.9-20 0.108 1
Female 455 43.4 327 22 18.8-25.1 0.87 0.75-1 0.05
Age
≤40 years 96 9.1 68 18 13.9-22 0.281 0.92 0.71-1.19 0.51
>40 and ≤60 years 559 53.4 420 21 17.7-24.2 1
>60 years 393 37.5 286 19 16.4-21.5 1.04 0.89-1.22 0.64
Radionuclide
Lutetium-177 378 36 236 17 14-19.9 <0.001 1.12 0.94-1.33 0.20
Yttrium-90 157 15 122 13 9.8-16.1 1.41 1.15-1.74 0.001
combined 513 49 416 24 21.2-26.7 1
Grading
G1 (Ki67<2%) 247 23.5 162 22 16.6-27.3 <0.001 0.86 0.71-1.05 0.14
G2 (Ki67 3-20%) 399 38.1 292 21 18.1-23.9 1
G3 (Ki67>20%) 67 6.4 58 7 5-8.9 1.72 1.29-2.3 <0.001
unknown 335 32 262 19 15.1-22.8 0.91 0.77-1.08 0.3
Previous therapies
0 119 11.4 45 24 8.3-39.6 <0.001 0.78 0.57-1.08 0.13
1 303 29 231 22 18.8-25.1 0.91 0.77-1.09 0.32
2-3 417 39.7 334 18 14.8-21.1 1
>3 209 19.9 164 17 12.4-21.5 1.18 0.97-1.43 0.10
Primary tumor
Bronchial 75 7.2 62 11 6.3-15.6 <0.001 1.43 1.08-1.91 0.01
Pancreas 384 36.7 303 20 17-22.9 1
Small Intestine 315 30 211 22 17.6-26.3 0.75 0.61-0.92 0.01
CUP 151 14.4 115 13 9.5-16.4 1.27 1.01-1.58 0.04
Other 123 11.7 83 20 13.9-26 0.83 0.64-1.06 0.14
Functional syndromes
Carcinoid 
syndrome 158 15 128 16 12.6-19.3 0.612 1.18 0.95-1.46 0.13
Gastrinoma 46 4.3 39 26 19.1-32.8 1.01 0.72-1.42 0.95
Insulinoma 15 1.4 13 28 12.5-43.4 0.95 0.54-1.66 0.86
31Glucagonoma 16 1.5 13 20 nr-40.1 0.94 0.54-1.66 0.85
VIPoma 8 0.7 6 22 14.6-29.3 0.79 0.35-1.79 0.59
Other 1 0.1 1 16 nr 1.96 0.27-14.3 0.52
None 804 76.7 574 19 16.9-21 1
Abbreviations: nr: not reached; 95 CI: 95% confidence interval bold figures indicate significance results.
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Origin of primary tumors influenced PFS. Patients 
with neuroendocrine neoplasias of small bowel had a 
longer PFS compared to patients with pancreatic NENs 
whereas bronchial origin und unknown origin was 
associated with a significantly shorter PFS in multi-
variate analysis (Figure 6A, Table 2). The 25 patients 
with medullary thyroid cancer had a median PFS1 of 
10.1 months (2-18.2). After an interval of more than 
6 months, 470 patients underwent re-PRRT. Median 
PFS2 was 11 months (Figure 7A; Supplementary Table 
1). Univariate analysis indicated statistically significant 
differences according to radionuclides, grading and origin 
Figure 5: Kaplan-Meier plots of progression-free survival 1 according to radioisotope (A) and grading (B).
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of neuroendocrine neoplasia but no influence of gender, 
age, number of previous therapies and functionality 
(Supplementary Table 1). In multi-variate analysis, these 
differences were attributable to significantly lower PFS in 
patients treated with 90Y solely (Supplemantary Table 1). 
Patients with unknown grading had a significantly longer 
progression free survival with a median of 11 months, 
as compared to 9 months in patients with G2 tumors 
(Supplementary Figure 4A, Supplementary Table 1).
In 184 patients, a re-re-PRRT was performed 
after an interval of more than 6 months after re-PRRT 
(Supplementary Table 2). Median PFS was 8 months 
Figure 6: Kaplan-Meier plots of progression-free survival 1 according to primary tumors (A) and number of previous therapies (B).
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(Figure 7B). Here, the small size of the different groups 
limited the analysis of statistical significance. Uni-variate 
and multi-variate analysis suggested a significantly longer 
PFS in female patients (Supplementary Table 2). Multi-
variate analysis indicated a shorter PFS in patients younger 
than 40 years and longer PFS in patients with unknown 
grading (Supplementary Figure 4B, Supplemenary Table 
2), however, these results were limited by the small 
numbers of sub-groups.
Adverse events
Adverse events were recorded according to patient 
and treatment cycle according to CTCAE criteria (Table 
3). Hemoglobin levels, number of leucocytes, platelets 
Figure 7: Kaplan-Meier plots of progression-free survival 2 (A) and 3 (B) after re-start of PRRT.
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and creatinine levels were determined before and after 
PRRT. After the initial PRRT (1048 cycles), grade 3 and 4 
adverse events were rare. Dialysis was performed before 
PRRT in 3 patients and continued thereafter. After 2633 
follow-up cycles, grade 3 and 4 adverse events were still 
prevalent in less than 1% of patients. Laboratory values 
were then studied across all 3692 cycles. Here, grade 3 
and 4 adverse events did not increase and were still below 
1%. Missing values were less than 1% (Table 3). Dialysis 
was necessary at any time after PRRT in additional 5 
patients of 1048 (0.4%) patients. During follow-up, MDS 
or leukemia developed in 22 (2%) patients (Table 4), 
which developed after a mean of 8 years after diagnosis 
of the neuroendocrine neoplasia and was most prevalent 
in patients with NEN of pancreatic or small bowel. 
Possible risk factors included previous chemotherapy and 
external beam radiation. Most patients developing MDS or 
leukemia had a high tumor load with hepatic metastases. 
Prognosis of patients with MDS/leukemia was dismal with 
a mean overall survival of 14.4 months after diagnosis 
(Table 4).
DISCUSSION
In our study, we report OS, PFS and adverse 
events of 1048 patients treated by PRRT over ten years. 
Limitations of our study is it retrospective nature and 
lack of control arms and random selectin for therapies. 
On the other hand, this is a large selection of patients 
treated in day-today practice yielding results useful in 
clinical settings. Just more than half of the cohort has 
survived during follow-up yielding exact overall survival 
data of patients and sub-groups. To ensure that all 
deceased patients were included in the analysis, several 
tracking mechanisms were employed at our institution as 
described above. Compared to historical controls [11], 
OS observed in our study is favorable implying that 
PRRT is effective. On the other hand, OS observed in our 
study may be mainly related to better differentiation of 
NEN since we included only patients with somatostatin 
receptor-expressing NEN. However, there appears to be no 
survival advantage of patients with somatostatin receptor-
expressing mid-gut neuroendocrine tumors compared to 
non-expressing tumors [18].
Treatment with both radioisotopes resulted in better 
OS than with 177Lu or 90Y solely. These results were also 
reported in another study. Combined application of 90Y- 
and 177Lu-based PRRT in patients with different NENs 
resulted in a median OS of 66.1 months [19], which is 
almost identical to the median OS of 64 months in our 
study. These results indicate that personalized treatment 
adapting radioisotopes and dose to tumor load and location 
is superior than more restricted protocols. However, it 
should be noted that PRRT as monotherapy may be not as 
effective as combinatory protocols using radiosensitizers 
such as Everolimus (Afinitor®) or a combination of 
capecitabine and temozolomide achieving higher response 
rates compared to PRRT alone [20, 21].
Another molecular target, the serine-threonine 
kinase mTOR plays a pivotal role in pathogenesis of NENs 
and is effectively inhibited by Everolimus (Afinitor®). 
A prospective placebo-controlled multi-center trial in 
patients with pancreatic NENs has shown prolongation of 
PFS in patients treated with Everolimus (Afinitor®) versus 
patients treated with placebo (11.0 versus 4.6 months). 
Although median PFS in patients treated with Everolimus 
(Afinitor®) is lower in patients with pancreatic NENs 
than 20 months observed in our study, a recent analysis 
has shown that patients treated initially with Everolimus 
(Afinitor®) have a median OS of 44 months [22], which 
corresponds exactly to the median OS in our study. Albeit 
these studies are difficult to compare due to different 
Table 3: Number of patients with adverse events according to CTCAE criteria
Before first PRRT (1048)
Normal, G1, G2 G3 G4 No information
Leucocytes 1047 (99.9%) 0 0 1
Thrombocytes 1047 (99.9%) 0 3 1
Hemoglobin 1040 (99.2%) 3 3 1
Chronic kidney disease 1040 (99.2%) 1 2 4 (0.3%)
According to treatment cycles (3692)
Normal, G1, G2 G3 G4 No information
Leucocytes 3680 (99.6%) 8 (0.2%) 0 4 (0.1%)
Thrombocytes 3679 (99.6%) 1 8 (0.2%) 4 (0.1%)
Hemoglobin 3666 (99.2%) 10 (0.2%) 7 9 (0.2%)
Chronic kidney disease 3664 (99.2%) 7 (0.1%) 7 (0.2%) 14 (0.3)
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Table 4: Characteristics of patients with MDS or leukemia after PRRT
Age at diagnosis 
of neuroendocrine 
neoplasia
Age at 
start of 
PRRT
Age at 
diagnosis 
of MDS/
leukemia
Radionuclides 
and dose
Type of 
MDS/
leukemia
Type and extend of 
neuroendocrine neoplasia Other risk factors Sex
Survival after 
diagnosis of 
MDS/leukemia 
(death or date 
last seen)
1 40 years 42 years 49 years
131Iodine 
MIBG 22.7 
GBq90Yttrium 
7.4 GBq
MDS
paraganglioma hepatic, 
lymphatic and osseous 
metastases
chemotherapy 
external beam 
radiation (40 Gy)
female 15 months
2 67 years 68 years 69 years
90Yttrium 8 
GBq177Lutetium 
6 GBq
RAEB/T
neuroendocrine carcinoma 
pancreas hepatic, lymphatic 
and osseous metastases
right sided 
heart disease 
hypertension
female 6 months
3 66 years 79 years 80 years
90Yttrium 9.5 
GBq 177Lutetium 
6.3 GBq
RAEB-1
neuroendocrine tumor of 
unknown primary hepatic 
metastases
right sided 
heart disease 
hypertension
female 16 months
4 63 years 64 years 66 years
90Yttrium 14 
GBq
RAEB/
AML
neuroendocrine tumor 
pancreas extensive hepatic 
metastases
chemotherapy 
interferon alpha male 8 months
5 66 years 67 years 69 years
90Yttrium 10.5 
GBq 177Lutetium 
4 GBq
acute 
leukemia
neuroendocrine carcinoma 
pancreas hepatic and 
lymphatic metastases
male 1 month
6 64 years 64 years 75 years
177Lutetium 8 
GBq RAEB-1
neuroendocrine tumor of the 
ileum lymphatic and hepatic 
metastases
external beam 
radiation (50 Gy) female 11months
7 50 years 68 years 71 years
90Yttrium 2.5 
GBq 177Lutetium 
17 GBq
RAEB-1
neuroendocrine tumor of the 
ileum lymphatic and osseus 
metastases
arterial 
hypertension 
obesity
female 43 months
8 69 years 69 years 70 years
90Yttrium 11.4 
GBq 177Lutetium 
6.5 GBq
P-CLL
neuroendocrine tumor of 
unknown primary hepatic 
metastases
diabetes 
coronary heart 
disease arterial 
hypertension
male 96 months
9 63 years 63 years 67 years
90Yttrium 6.9 
GBq 177Lutetium 
27.3 GBq
MDS 
(CMML-1)
neuroendocrine tumor of the 
pancreas lymphatic and bone 
metastases
chemotherapy 
external beam 
radiation
male 8 months
10 69 years 70 years 70 years 90Yttrium 6 GBq MDS RAEB-1
neuroendocrine tumor of 
the ileum extensive hepatic 
metastases
female 24 months
11 45 years 57 years 66 years
90Yttrium 16.6 
GBq 177Lutetium 
11 GBq
MDS 
RAEB-1
neuroendocrine carcinoma 
of the duodenum hepatic 
metastases
multiple 
chemotherapies 
Interferon alpha
female 16 months
12 51 years 52 years 58 years
90Yttrium 8 GBq 
177Lutetium 22.5 
GBq
MDS 
RAEB-1
pancreatic neuroendocrine 
neoplasma Lymphatic, 
osseus and extensive hepatic 
metastases
diabetes male 8 months
13 69 years 70 years 71 years
90Yttrium 9.2 
GBq 177Lutetium 
12.7 GBq
t-MDS 
RAEB-2
pancreatic neuroendocrine 
neoplasma osseus and 
extensive hepatic metastases
chemotherapy male 16 months
14 58 years 73 years 79 years
177Lutetium 22.5 
GBq AML MO
neuroendocrine neoplasma of 
ileum peritoneal and hepatic 
metastases
chemotherapy 
arterial 
hypertension
female 10 months
15 63 years 63 years 66 years
177Lutetium 26.3 
GBq
MDS 
RAEB-1
neuroendocrine neoplasma 
of ileum Peritoneal, pleural, 
osseus and lymphatic 
metastases
external beam 
radiation carcinoid 
heart disease
female 6 months
16 49 years 52 years 57 years
90Yttrium 9.5 
GBq 177Lutetium 
11.7 GBq
MDS 
RAEB-1
pancreatic neuroendocrine 
neoplasma extensive lymphatic 
and hepatic metastases
female 16 months
17 71 years 73 years 75 years
90Yttrium 6.7 
GBq 177Lutetium 
6.9 GBq
AML 
EGIL
pancreatic neuroendocrine 
neoplasma extensive 
lymphatic, osseus and hepatic 
metastases
arterial 
hypertension 
diabetes mellitus
male 24 months
(Continued)
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Age at diagnosis 
of neuroendocrine 
neoplasia
Age at 
start of 
PRRT
Age at 
diagnosis 
of MDS/
leukemia
Radionuclides 
and dose
Type of 
MDS/
leukemia
Type and extend of 
neuroendocrine neoplasia Other risk factors Sex
Survival after 
diagnosis of 
MDS/leukemia 
(death or date 
last seen)
18 41 years 46 years 50 years
90Yttrium 8 GBq 
177Lutetium 17.5 
GBq
MDS 
RAEB-1
functionally active 
neuroendocrine neoplasm of 
ileum (carcinoid) extensive 
hepatic, bone, lymphatic and 
pleural metastases
external beam 
radiation diabetes 
mellitus
male 4 months
19 68 years 69 years 75 years
90Yttrium 5.2 
GBq 177Lutetium 
27.6 GBq
MDS 
RAEB-1
functionally active pancreatic 
neuroendocrine neoplasma 
(gastrinoma) lymphatic and 
extensive hepatic metastases
chemotherapy 
transarterial 
chemoembolisation 
molecular therapy
female 9 months
20 52 years 59 years 61 years
177Lutetium 21.7 
GBq
MDS 
RAEB-2
typical carcinoid of the lung 
extensive hepatic and osseus 
metastases
selective internal 
radiotherapy 
external beam 
radiation 
hypertension
male 6 months
21 61 years 64 years 65 years
177Lutetium 8.5 
GBq
MDS 
RAEB-1 
AML
functionally active 
neuroendocrine neoplasm of 
ileum (carcinoid) extensive 
hepatic metastases
multiple TACE 
carcinoid heart 
disease arterial 
hypertension 
interferon therapy
male 16 months
22 53 years 53 years 63 years
90Yttrium 2 GBq 
177Lutetium 48 
GBq
MDS 
RAEB-1
pancreatic neuroendocrine 
neoplasma extensive 
lymphatic, osseous and hepatic 
metastases
chemotherapy female 2 months
Ø 58.9 years 62.9 years
66.9 
years 21.7 GBq
MDS 
unspecified 
1 RAEB-
1 12 
RAEB-2 3 
RAEB-T 
1 AML 3 
pCLL 1
Paraganglioma 1 SiNET 7 
pNET (& duodenum) 9 CUP 
2 Lung 1 Functionally active 
2/21
ext. beam radiation 
5 chemotherapy 
8 carcinoid 
heart disease 4 
interferon 3 art. 
hypertension 6 
diabetes 3
12 
female 
10 
male
14.4 months
Abbreviations: AML: acute myeloid leukemia; Ci: Curie; MDS: myelodysplastic syndrome; Gy: Gray; RAEB: refractory anemia with excess blasts; 
extensive hepatic metastases were defined as more than 50% infiltration of the liver data cut off for survival after diagnosis of MDS was 06-23-2016.
design, these results corroborated clinical significance of 
hitting key molecular pathways in treatment of NENs.
OS was significantly determined by gender, age, 
radionuclides, number of previous therapies and origin 
of tumors in uni- and multi-variate analysis whereas 
functionality of NENs was significantly different only in 
uni-variate but not in multi-variate analysis. The patients 
with G1 tumors had the best OS, and so also did those 
with an age of a less than 40 years at diagnosis, patients 
treated with a combination of 90Y and 177Lu, and in NENs 
of small bowel. The OS of patients with G3 NENs was 
favorable. However, it is likely that this subgroup reflects 
mainly well differentiated neuroendocrine carcinomas due 
to the expression of somatostatin receptors. This group 
most likely reflects the newly created classification of 
neuroendocrine tumor G3, which is limited to NENs with 
a proliferation rate of up to 50% [3]. Indeed, OS of patients 
with a proliferation rate of more than 50% had a shorter OS 
than the whole group. These differences reflect biological 
characteristics of NENS, which should be included in 
clinical practice when planning PRRT and follow-up.
Follow-up in our patients was performed with 68Ga-
SSTR PET/CT and EORTC criteria as well as RECIST 
[23]. Median PFS was 19 months in all patients, which 
is considerably shorter than the median of 41 months 
determined by RECIST 1.1 in a multi-institutional study 
in Germany involving 450 patients [11]. Shorter PFS by 
SSTR PET/CT follow-up reflects the increased sensitivity 
of this novel method. Although, 68Ga-SSTR PET/CT is 
very accurate for estimating the therapy response and 
especially for patient selection for PRRT, we postulate 
that PFS calculated solely on the basis of PET/CT be 
judged with caution. It should be kept in mind that 
EORTC criteria were primarily meant for the assessment 
of tumor response in lymphomas on 18F-FDG PET/CT. 
The different principle of assessment (SSTR status vs 
glucose metabolism) of NENs by this molecular imaging 
technique has to be born in mind. Probably, there is a need 
for newer response assessment criteria (for e.g., based on 
SUV tumor-to-spleen ratio, molecular tumor volume), 
designed on the basis of future prospective studies. In 
fact, median PFS determined by SSTR PET/CT using 
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EORTC criteria does not mandatorily mirror OS in sub-
groups with divergent prognosis. In fact, median PFS 
was not significantly different according to gender and 
age. Overall survival advantage of patient treated with a 
combination of 90Y and 177Lu (64 months) compared to sole 
usage of 177Lutetium (44 months) was not exactly reflected 
in median PFS times of 24 and 17 months, respectively, 
although showing a similar trend. Only exclusive usage 
of 90Y as radionuclide for PRRT resulted in significant 
lower PFS of 7 months compared to combined use (24 
months). Likewise, OS advantage of patients with G1 
NEN compared to G2 NEN (88 months versus 55 months) 
was not translated into PFS, which was 22 months for 
G1 tumors and 21 months for G2 NENs. However, G3 
NENs had a lower OS and PFS. Number of previous 
therapies and functionality had no significant effect upon 
median PFS in multi-variate analysis. Median PFS in 
NENs of bronchial or unknown primary was significantly 
lower compared to pancreatic NENs in multi-variate 
analysis. Interestingly, the significantly lower median 
PFS of NENs of unknown primary (13 months versus 20 
months in pancreatic NENs) was not reflected in median 
OS, which was not significantly different in both sub-
groups (53 versus 44 months). We were able to include a 
subgroup of patients with somatostatin receptor positive 
medullary thyroid cancer in our analysis. Median OS of 
these patients was promising with 32 months median OS 
and 10.1 months PFS1, which should be examined in 
larger studies comparing standard treatments and peptide 
receptor radionuclide therapy.
These results indicate that progression documented 
by a sensitive method does not necessarily affect OS and 
should be considered in clinical practice. A criteria/scoring 
for somatostatin receptor PET/CT in NETs including 
for molecular response assessment, similar to for e.g., 
Krenning’s score for somatostatin receptor scintigraphy, 
needs to be developed and standardized.
Patients with NENs often require multi-disciplinary 
treatment with several lines of systemic therapy, often 
resulting in side effects depending on the therapy involved. 
Hemo- and nephrotoxicity are well known adverse events 
of PRRT [11, 24–27]. We monitored adverse events in 
our study by screening laboratory measurements during 
the 3692 treatment cycles. Here, we found grade 3 and 
4 adverse events in less than 1% of PRRT cycles. There 
could be a possible underestimation of the real extent, 
since long term effects may be potentially missed. 
Therefore, we performed an additional search in all 
patient files and also obtained extensive information from 
the family physician to look into any hematological and 
nephrological toxicities during follow-up. We identified 
22 subjects with leukemia/MDS and 5 additional patients 
(0.4%) with chronic kidney disease requiring hemodialysis 
after PRRT, whereas 3 patients had already been on 
hemodialysis before PRRT due to other reasons. Recently, 
incidence of leukemia and MDS after PRRT was reviewed 
by Bodei et al. [26] and Kesavan & Turner [25] reporting 
rates of 2% and 1.4%, respectively which corresponds to 
the 2.1% in our study. Risk factors identified in our study 
were chemotherapy and external beam radiation, as well 
as high tumor loads defined as involvement of more than 
50% of the liver, multiple/multifocal (<10) bone and 
lymph node metatases. Development of leukemia/MDS 
after PRRT is associated with a limited mean overall 
survival of 14.4 months in our study. Rates of permanent 
severe nephrotoxicity of grade ≥4 have been described 
in as high as 9.2% in a study applying high doses of 90Y 
exclusively [24]. In contrast, severe nephrotoxicity is rare 
in patients treated by PRRT with 177Lu [28]. Incidence of 
severe renal impairments in our study was much lower, 
due to the mandatory renal protection followed as well as 
proper hydration of the patient after therapy.
MATERIALS AND METHODS
Patients
Between 2004 and 2014, 2294 patients were referred 
to Zentralklinik Bad Berka, Germany for diagnosis and 
treatment of NENs. Of these, 570 were found to be not 
eligible for PRRT and 676 patients, although eligible, did 
not undergo the treatment for various reasons (e.g. decision 
was reached in the interdisciplinary tumor board to 
perform first a different kind of therapy like transcatheter 
arterial chemoembolisation due to high functionality of the 
tumor). The criteria used to define eligibility for PRRT 
were in conformation with the published guidelines for 
PRRT [29] and included a Karnofsky of more than 60%, 
life expectancy of more than 6 months, somatostatin 
receptor positive NENs and adequate renal and bone 
marrow function. Excluded were patients not matching 
these criteria and somatostatin receptor negative NENs. 
Thus, PRRT was performed in 1048 patients and all of 
them were included in the intention to treat analysis 
(Figure 1). Before PRRT, patients were extensively 
informed about the procedure and the possible side effects. 
Written informed consent was obtained from all patients, 
which included permission for data storage and analysis. 
In 2007, the responsible ethical committee permitted 
retrospective and prospective data collection and analysis 
by the German neuroendocrine tumor registry, which 
was renewed in 2014. Data collection was performed in 
accordance with the registry. Decision to treat the patients 
by PRRT was taken by internal or external tumor boards. 
All patients were studied by SSTR PET/CT using 68Ga-
DOTANOC, 68Ga-DOTATOC, or 68Ga-DOTATATE 
prior to PRRT, which was also used for patient follow-
up. All patients were either progressive before PRRT, as 
determined by morphological imaging (CT or MRI) or 
by SSTR PET/CT, or were severely symptomatic due to 
extensive tumor mass or functional syndromes.
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Radiopharmaceuticals
The DOTA-conjugated somatostatin analogues 
DOTA-TOC,-NOC and -TATE were labeled with 68Ga, 
177Lu and 90Y in our radiopharmacy department in 
accordance with good medical practice. The radionuclide 
68Ga was obtained in house from the 68Geranium-68Ga 
generator (Eckert and Ziegler GmbH, Berlin, Germany). 
A highly efficient NaCl-based labeling procedure for the 
radiopharmaceutical production of 68Ga labeled ligand-
conjugate has been developed in our hospital [30, 31]. 
177Lu and 90Y were obtained from different manufacturers. 
The labeling of DOTA-conjugated peptides with 177Lu 
(also applicable to 90Y) was performed according to a 
previously published method [32].
68Ga-SSTR PET/CT
PET/CT (until January 2014 with Siemens 
Biograph and since then with Biograph mCT Flow 64; 
Siemens Medical Solutions AG, Erlangen, Germany) was 
performed in all cases 45-90 minutes after the intravenous 
injection of 46-260 MBq of 68Ga-DOTANOC, -DOTATOC 
or DOTATATE. PET/CT images were acquired from the 
skull to the middle part of the thigh. Contrast-enhanced 
CT (ceCT, spiral CT using Biograph mCT Flow 64) was 
acquired after intravenous administration of 60-100 mL 
nonionic iodinated contrast. Images were evaluated by 
two experienced nuclear medicine specialists. Any area 
with intensity greater than background and that could 
not be explained by physiologic activity was considered 
to be indicative of tumor tissue. Maximum standardized 
uptake values (SUVmax) were obtained by drawing circular 
regions of interest (ROIs), which were automatically 
adapted (40% isocontour) to a 3D volume of interest using 
commercial software provided by the vendor.
Infusion and renal protection
Kidney protection was performed using an infusion 
of 1600 mL of a renoprotective amino-acid mixture of 
5% lysine HCl and 10% L-arginine HCl. The infusion 
was started at least 30 min prior to administration of the 
therapeutic dose and continued for 4 h thereafter. The 
radiopharmaceutical was co-administered over 10–15 min 
by using a second infusion pump system. The activity to 
administer was individually chosen based on the uptake 
in the tumor lesions as shown by 68Ga-SSTR PET/CT 
(performed before each treatment cycle), kidney function 
(assessed using the following: tubular extraction rate 
determined by 99mTc-MAG3 scintigraphy, glomerular 
filtration determined by 99mTc-DTPA clearance, and serum 
creatinine), hematological reserve, previous treatments 
and general status of the patient (Karnofsky Performance 
Scale) [32–34]. Decision to use 90Y and/or 177Lu depended 
upon tumor mass, SUV and radionuclide availability 
[24]. Both radionuclides were used in subsets of patients 
sequentially (DUO) or in combination (TANDEM)[19, 35].
PRRT
The intention to treat analysis included 1048 
patients, who received 3692 cycles of PRRT. Most patients 
received a combination of 90Y and 177Lu (49%), whereas 
36% patients were only treated with 177Lu and 15% with 
90Y, exclusively. PRRT with 90Y was performed in 371 
cycles, applying a mean activity of 3.18 GBq, whereas 
with 177Lu was administered solely in 1043 cycles with 
a mean applied activity of 6.54 GBq. Dosimetry was 
performed after each cycle. Administered activity 
depended on patient and tumor-related factors like weight, 
renal function, tumor burden, clinical course and previous 
dosimetry. DUO-PRRT, i.e., application of 177Lu and 90Y 
in subsequent cycles in a particular patient, comprised 
1235 cycles with 177Lu (mean administered activity 6.55 
GBq) and 1008 cycles with 90Y (mean activity 3.36 GBq). 
TANDEM-PRRT, i.e., treatment with a combination of 
177Lu and 90Y-labeled somatostatin analogues administered 
on the same day, was performed in 35 cycles with a mean 
implemented activity of 3.06 and 4.65 GBq, respectively.
Efficacy and safety
Restaging was performed with SSTR-PET/CT 3-6 
months after PRRT. In case of stable disease or remission 
(complete or partial), the patient was restaged with SSTR 
PET/CT every 6-12 months until disease progression 
was evident on imaging. In addition, MRI in selected 
cases (allergy to iodinated contrast or poor detectability 
of liver metastases on CT scan) and routine sonography 
were performed for additional diagnostic evaluation. 
Resumption of PRRT after detection of progression after 
a therapy interruption of more than 6 months (2nd phase of 
PRRT) was performed in 470 patients. The next (second) 
resumption of PRRT (3rd phase of PRRT) after progression 
post 2nd phase of PRRT after an additional interval of 
more than 6 months was implemented in 184 patients. 
Laboratory parameters (erythrocytes, haemoglobin, 
platelets, leucocytes, creatinine, BUN, SGOT, SGPT, 
bilirubin, SAP, TSH, SGamma-GT and respective 
tumor markers) were evaluated prior to each cycle and 
at restaging. Renal function was monitored by tubular 
extraction rate (TER) using 99mTc-MAG3 renography 
and in addition the glomerular filtration rate (GFR) was 
determined using 99mTc-DTPA renography.
Method of patient documentation
A database was established in 2004 including 
more than 250 items for all patients with at least 
one cycle of PRRT. Out of this database, items were 
extracted to allow analysis of overall and progression-
free survival according to age, sex, number and kind 
Oncotarget16948www.oncotarget.com
of pretreatments, grading, differentiation, methods of 
PRRT and administered radioactivity as well as origin 
of primary tumors and presence and kind of functional 
syndromes. Adverse events were determined according 
to CTCAE criteria version 4.03 by assessing all available 
laboratory measurements. In addition, adverse events were 
documented in an additional dataset by incoming patient 
reports during follow-up. Clinical data from the patient file 
as well as during patient registration by trained physician 
assistants. Data analysis was performed on anonymized 
data sets. All patients irrespective of tumor stage or 
prognosis, received an appointment for follow-up. When 
patients did not appear, their family and/or physicians 
were contacted. In addition, all patients were invited once 
yearly to a patient conference organized by our hospital. 
Date of death was reported by family physicians. No 
patient was lost to follow-up.
Statistical analysis
We assessed overall survival and progression-
free survival with Kaplan-Meier curves and compared 
subgroups with one-sided log rank test. Univariate and 
multivariate analyses were done in R version 3.0.0 and 
rms package [36]. Uni-variate analysis was done by fitting 
an analysis of variance model to each variable under 
investigation [37]. Multi-variate analysis was conducted 
using Cox models [38]. Responses were evaluated with 
EORTC criteria (PET component of PET/CT) as well as 
by RECIST (CT component of PET/CT or MRI) [39]. 
Adverse events were assessed from lab data and graded 
according to CTCAE criteria.
CONCLUSIONS
Treatment of patients with NENs by PRRT has 
demonstrated favorable and clinical significant median OS 
and PFS with minimal acceptable side effects, observed 
during a treatment period of a decade. Follow-up by 
somatostatin receptor PET/CT is feasible and effective, 
however, progression documented by this sensitive 
method should be always evaluated in clinical context.
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